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Background: Chemotherapy-induced nausea and vomiting is one of the most influential factors that affect patient
quality of life; thus, preventing this adverse event could lead to better patient outcome. Standard preventive
guidelines for antiemetic treatment have already been established based on the emetogenicity of chemotherapeutic
agents. It is important that compliance with in-house guidelines and their effect on patient outcome is monitored.
Methods: In 3 years since the Akita university hospital antiemetic guidelines were outlined, we assessed the incidence
of chemotherapy-induced nausea and vomiting using the antiemesis tool of the Multinational Association of Supportive
Care in Cancer. Compliance of the guidelines was extracted from the hospital clinical record, and the chemotherapy-
induced nausea and vomiting was examined by the patient reported outcome.
Results: Seventy-three patients answered the questionnaire. The overall compliance rate with the guidelines for early
nausea and vomiting was 98.6% and with the delayed nausea and vomiting was 87.7%. The complete response rate for
the early and delayed chemotherapy-induced nausea and vomiting was 77.8% and 73.8%, respectively. The overall
relative risk of early nausea and vomiting was 0.22 (P < 0.05), whereas the relative risk for delayed nausea and vomiting
was 2.09 (P < 0.05). Breakthrough vomiting was observed in 3 cases in the low-risk group only. These data suggest that
delayed nausea and vomiting is difficult to prevent, particularly in the low-risk group. Further, it seems that the individual
sensitivity for emetogenicity might differ among patients.
Conclusions: In addition to standard prevention guidelines based on emetogenicity, individual care based on patient
reports should be considered for the complete prevention of chemotherapy-induced nausea and vomiting.
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One of the most devastating effects on the quality of life
(QOL) of cancer patients is chemotherapy-induced nau-
sea and vomiting (CINV). CINV is believed to affect
70%–80% of patients that receive cancer chemotherapy
[1]. In addition, even effective chemotherapy may be
stopped because of severe CINV, and the clinical losses
may be significant in these cases [2].* Correspondence: hiroyuki@med.akita-u.ac.jp
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unless otherwise stated.The underlying mechanisms that cause CINV have
been determined gradually, and many neurotransmitters
such as 5-hydroxytryptamine (5-HT3, serotonin) and
substance P are involved in CINV [3]. 5-HT3 receptor
antagonists (5-HT3RA) such as granisetron, ondanse-
tron, and palonosetron have been approved for the treat-
ment of CINV [4]. In addition, aprepitant was approved
as a substance P blocker and a neurokinin 1 (NK1) re-
ceptor antagonist (NK1RA) for the prevention of acute
and delayed CINV [4]. These agents have greatly im-
proved patient outcome regarding CINV. For example, it
was reported that a complete response of CINV occurred
in 53.6%–53.7% of patients that received moderatelyhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Schematic presentation of this study. Comparison
between compliance of anti-emetic guideline and patient reported
outcome.
Table 1 Patients’ characteristics
Number of participant 73
Age (median) 28-79 (62)
Male: Female 36: 37










Acute lymphoblastic leukemia 1
Malignant myeloma 2
Prostate cancer 5
Renal cell carcinoma 1
Cancer of unknown primary 4
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methasone (DEX) [5]. It was also reported that, among
patients receiving cisplatin-based chemotherapy, the ad-
vantage achieved by the use of aprepitant was 20 percent-
age points [6].
Since the Multinational Association of Supportive Care
in Cancer (MASCC) released their antiemetic guidelines
in 1998, the American Society of Clinical Oncology
(ASCO) and the National Comprehensive Cancer Net-
work (NCCN) also released guidelines for the prevention
and treatment of CINV [7]. Antiemetic strategies primar-
ily using 5-HT3RA, NK1RA, and DEX have been estab-
lished and recommended based on four emetogenicities
(high, moderate, low, and minimal risk) for each chemo-
therapeutic agent [7]. In individual institutions, in-house
guidelines for the prevention and treatment of CINV ac-
cording to the MASCC, ASCO, and NCCN guidelines
have been created and implemented, including in our hos-
pital. Added to these guidelines, it is very important to
monitor both patient outcome and their compliance with
the guidelines [8]. However, because awareness of the oc-
currence of CINV depends only on patient declarations, it
is difficult to know the severity of the CINV without
patient-reported outcomes. In the current study, we
assessed the consistency between the CINV compliance
guidelines set in 2010 in Akita University Hospital and the
outcome of patients visiting the Division of Chemotherapy
for Outpatients. In this observational study, we revealed
that the individual monitoring of CINV, even in low-risk
emetogenicity patients, is very important to improve pa-
tient QOL during chemotherapy.
Methods
Patients who visited the Division of Chemotherapy for
Outpatients, Akita University Hospital, between November
2013 and March 2014 were asked about their early and
delayed CINV using the Japanese version of the MASCC
Antiemesis Tool (MAT) [9], which was administered at a
usual medical examination using a questionnaire. The
grade of nausea was rated from 1 to 10 (1, minimum; 10,
maximum), and the number of times of vomiting was re-
corded by the patients themselves. Questions were asked
at any time during treatment, but only once for each
patient. Conducted chemotherapeutic and anti-emetic
agents were extracted from electronic clinical record of
hospital, and the compliance of guideline was examined.
Further, comparison was made between the patient re-
ported outcome and the compliance of guideline (Figure 1).
Stat Mate III (ATMS, Tokyo, Japan) was used to calculate
the relative risk. The level of statistical significance was set
as P < 0.05. This retrospective study was approved by the
Ethics Committee of the School of Medicine of Akita Uni-
versity. Written informed consent for participation in the
study was obtained from participants.Results and discussion
Patients
The patients included 36 males and 37 females aged 28–
79 years, with a median age of 62 years (Table 1). The
patients were diagnosed with the malignancies listed in
Table 1. Colorectal cancer was most frequent (16/73),
followed by breast (13/73), lung (9/73), and gastric can-
cers (9/73). All participants were diagnosed as suitable
for chemotherapy as outpatients, without any clinical
signs of brain metastasis or intestinal obstructions. The
performance status of all participants was below 2, ac-
cording to the Eastern Cooperative Oncology Group.
The detailed clinical information such as clinical stages,
Table 2 Treatment regimens and emetogenisity





Early; (−), Delayed; (−) Tmab + VNR 2
Tmab 2
VNR 1




Early; DEX, Delayed; (−) GEM 8
S-1 + GEM 1
nab-PTX + GEM 1
nab-PTX 3
Tmab + PTX 2
PTX 1
DTX + S-1 2
DTX + EMP 1
DTX + PSL 4
DTX 9
eribulin 1





Early; NK1RA+ 5-HT3RA +
DEX, or 5-HT3RA+DEX,
Delayed; NK1RA+
5-HT3RA + DEX, or
5-HT3RA + DEX
Bmab + CBDCA + PTX 3
Pmab + FOLFOX6 2
Bmab + CapeOX 1
CapeOX 3
SOX 1
Bmab + FOLFIRI 1






Early; NK1RA+ 5-HT3RA +
DEX, Delayed; NK1RA+
5-HT3RA + DEX




Tmab; Trastuzumab, VNR; vinorelbine, MTX; Methotrexate, VCR; Vincristine,
PSL; Prednisolone, GEM; Gemcitabine, nab-PTX; nab-Paclitaxel, DTX; Docetaxel,
EMP; estramustine, Bmab; Bevacizumab, sLV5FU2; simplified biweekly 5-FU &
leucovorin, VTD; bortezomib, thalidomide, dexamethasone, CBDCA; Carboplatin,
FOLFOX6; combination of Oxaliplatin and 5FU, CapeOX; capecitabine plus
intermittent oxaliplatin, SOX; S-1 plus intermittent oxaliplatin, FOLFIRI; combination
of Irinotecan and 5FU IRIS; CPT-11; Irinotecan, VCD; bortezomib, Cyclophosphamide,
dexamethasone, CDDP; Cisplatin, FEC; 5FU, Epirubicin, Cyclophosphamide,
EC; Epirubicin, Cyclophosphamide, R-CHOP; Rituximab, Cyclophosphamide,
Doxorubicin, Vincristine, Prednisolone.
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Chemotherapy naïve, and the other patients experienced
≥2 cycles of chemotherapy.
Regimens
The regimens used to treat the patients and their emetic
risks are listed in Table 2. The most frequent regimen was
docetaxel alone (9/73), followed by gemcitabine (8/73).
The regimens were divided into four emetic risk groups:
high, moderate, low, and minimal risks. The number of
patients receiving high-, moderate-, low-, and minimal-
risk regimens was 11, 17, 38, and 7, respectively.
Compliance with the antiemetic guideline
The compliance of the antiemetic guideline was exam-
ined. Our anti-emetic guideline is indicated in Table 3.
Sufficient antiemetic treatments were performed for the
minimal-risk regimens in all patients. In the low-risk
group, all except 1 case received sufficient treatments;
one under treatment was performed in the early phase,
and no under treatments were performed in the delayed
phase. For the moderate-risk group, sufficient treatments
were performed in 14 of cases (82.4%); no under treat-
ments occurred in the early phase, whereas three under
treatments were performed in the delayed phase. For the
high-risk group, sufficient treatments were performed in
6 cases (54.5%); no under treatments occurred in the
early phase, whereas five under treatments were per-
formed in the delayed phase. The overall compliance
rate was 87.7%; the compliance rate was 98.6% with early
phase CINV. The compliance rate for delayed phase
CINV was 87.7%; specifically, 97.4% in the low-risk
group, 82.4% in the moderate group, and 54.5% in the
high-risk group.
Comparison between patient outcome and compliance
with the guidelines
We next compared the patient-reported CINV and the
compliance of guideline. As shown in Figure 2, early
CINV was not prevented in 22.2% of cases, although the
sufficient antiemetic treatment against was conducted.
However, early CINV was not prevented at all in the
under treatment case. The overall relative risk for compli-
ance with the guidelines was calculated to be 0.22 (P <
0.05). Specifically, in the minimal-risk group, CIN was not
prevented in one of 7 cases (14.3%), in spite of sufficient
treatment (the grade of nausea was 2 (G2)). In the low-
risk group, CIN was not prevented in 8 of 37 cases
(21.6%) (G1 to G5; median = G2.5). Among these, one pa-
tient vomited once (2.7%). In the moderate-risk group,
CIN was not prevented in 2 of 7 cases (11.8%) (G2 to G4;
median = G3), but no CIV was observed. In the high-risk
group, CIN was not prevented in 5 of 11 cases (45.5%)
(G1 to G6; median = G3), but no CIV was observed.Delayed CINV was not prevented in 17 of the 65 cases
(26.2%), even though sufficient antiemetic treatments
were conducted (Figure 3). In the under treatment cases,
CINV (G1) was not prevented in 1 of 8 cases (12.5%).
Table 3 Compliance of antiemetic treatment
Emetogenisity Actual measure (Early) Actual measure (Delayed) n Compliance
Minimal 5-HT3RA + DEX no 2 Sufficient
5-HT3RA no 1 Sufficient
DEX no 1 Sufficient
no no 3 Sufficient
Low 5-HT3RA + DEX no 29 Sufficient
5-HT3RA + DEX DEX 3 Sufficient
5-HT3RA + DEX D2RA 1 Sufficient
DEX DEX 1 Sufficient
DEX no 3 Sufficient
no no 1 Insufficient
Moderate 5-HT3RA + DEX DEX 6 Sufficient
5-HT3RA + DEX NK1RA + DEX 3 Sufficient
NK1RA + 5-HT3RA + DEX NK1RA 2 Sufficient
NK1RA + 5-HT3RA + steroid (MM) NK1RA 1 Sufficient
NK1RA + 5-HT3RA + DEX 5-HT3RA + DEX + NK1RA 1 Sufficient
5-HT3RA + DEX no 3 Insufficient
5-HT3RA + DEX DEX + D2RA 1 Sufficient
High NK1RA + 5-HT3RA + DEX NK1RA 2 Insufficient
NK1RA + 5-HT3RA + steroid (ML) NK1RA 2 Sufficient
NK1RA + 5-HT3RA + steroid (ML) NK1RA + D2RA 1 Sufficient
5-HT3RA + DEX DEX 2 Insufficient
5-HT3RA + DEX no 1 Insufficient
5-HT3RA; 5-HT3 receptor antagonist, DEX; Dexamethasone, D2RA; Dopamine receptor D2 receptor antagonist, NK1RA; Neurokinin 1 receptor antagonist,
MM; multiple myeloma, ML; malignant lymphoma.
Figure 2 Patient-reported outcome regarding early CINV in
patients treated with sufficient antiemetic guidelines. Mini,
minimal-risk group; mod, moderate-risk group. An open circle
indicates the case with a complete response. The shaded circle
indicates CIN (the number corresponds to the grade of nausea). The
closed rectangle indicates CIV (the number corresponds to the number
of times of vomiting).
Figure 3 Patient-reported outcome regarding delayed CINV in
patients treated with sufficient antiemetic guidelines. Mini,
minimal-risk group; mod, moderate-risk group. An open circle indicates
the case with a complete response. The shaded circle indicates CIN
(the number corresponds to the grade of nausea). The closed rectangle
indicates CIV (the number corresponds to the number of times of
vomiting).
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0.05). Specifically, in the minimal-risk group, CIN was
not prevented in 1 of 7 cases (14.3%) (G3). In the low-
risk group, CIN was not prevented in 11 of 38 cases
(29.0%) (G1 to G4; median = G3). Among these, three
patients vomited (two patients twice and one patient
once). In the moderate-risk group, CIN was not pre-
vented in 2 of 14 cases (14.3%) (G1 to G5; median =
G3), but there were no instances of vomiting. In the
high-risk group, CIN was not prevented in 3 of 6 cases
(50%) (G1 to G4; median = G4), but there was no
vomiting.
In this observational study, CIV occurred only in the
patients that received low emetogenic chemotherapeutic
agents. One male patient (71 years old) that reported
early CIV was treated for the second time with nab-
pactlitaxel for his carcinoma of unknown origin, medias-
tinal lymph node metastasis, and pleural dissemination.
The remaining three patients claimed breakthrough
CIV. Of these, one female patient (42 years old) was
treated for the fourth time with eribulin for breast can-
cer with bone and liver metastases. Another female pa-
tient (61 years old) was treated with docetaxel for the
second time for lung cancer with asymptomatic and
multiple micrometastases in the brain. Finally, one male
patient (55 years old) was treated for the twelfth time
with docetaxel for lung cancer and cancerous pleuritis.
The compliance rate of our hospital was better than that
reported previously [10]. Preventive treatment against
early CINV was almost completely effective; however,
the prevention of delayed CINV was not sufficient in the
high-risk group according to the current guidelines. It is
necessary to prevent delayed CINV. According to the
patient-reported outcome, delayed CINV occurred in
only 12.5% of the patients that were treated with anti-
emetic agents insufficiently. However, early and delayed
CIN occurred in 22.2% and 26.2% of patients, respect-
ively, in spite of conduction of sufficient anti-emetic
treatment, particularly, in the high-risk group, early and
delayed CIN occurred in 45.5% and 50.0% of patients,
respectively. However, the grade of CIN was not so se-
vere (The median grade of early CIN = G3. and delayed
CIN = G4). Moreover, no CIV (breakthrough CIV) was
reported. The guidelines for the prevention of CINV in
the high-risk group appeared to be effective to compar-
able extent. In the low-risk group, early and delayed
CINV occurred in 21.6% and 28.9% of patients, respect-
ively, in spite of sufficient anti-emetic treatment (The
median grade of the early and the delayed CIN = G2.5
and G3, respectively). Moreover, 3 cases of breakthrough
CIV were reported. Among these, all three vomited sev-
eral times. These data suggest that compliance with the
guideline alone could not prevent emetogenicity. Con-
sistent with this, a previous study also reported thatsufficient measures could not prevent breakthrough
CIV completely, even in low-risk patients [11]. In
addition, some reports have discussed the difficulty of
prevention using antiemetic guidelines for delayed
CINV [12,13]. In particular, prevention in low-risk pa-
tients remains controversial.
Current guidelines are based primarily on the emeto-
genicity of chemotherapeutic agents. Data suggested that
individual differences in the sensitivity to antiemetic
treatments may occur. There are also too many individ-
ual parameters, including exposure to chemotherapy, al-
cohol use, age, and gender [14,15]. As such, data should
be gathered and analyzed regarding CINV cases. Such
factors may include individual sensitivities to the pre-
ventive agents, tumor status, and the physical condition
of patient. Refining the antiemetic measures is also ne-
cessary; accordingly, some methods have been proposed
[13,16]. However, the establishment of the personalized
precautions as well as the standard one is likely to be ne-
cessary for the complete prevention of CINV.Conclusions
The generation of antiemetic guidelines might contribute
toward patient compliance with antiemetic measures.
However, complete prevention remains challenging be-
cause individual factors should be considered.Additional file
Additional file 1: Table S1. Detailed characteristics of participants.
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